1. Home
  2. HWC vs TGTX Comparison

HWC vs TGTX Comparison

Compare HWC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hancock Whitney Corporation

HWC

Hancock Whitney Corporation

HOLD

Current Price

$63.60

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$33.22

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWC
TGTX
Founded
1883
1993
Country
United States
United States
Employees
3603
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
4.9B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
HWC
TGTX
Price
$63.60
$33.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$76.14
$49.80
AVG Volume (30 Days)
773.2K
1.9M
Earning Date
04-21-2026
05-04-2026
Dividend Yield
3.21%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
2.77
Revenue
N/A
$2,785,000.00
Revenue This Year
$11.66
$49.30
Revenue Next Year
$4.36
$24.55
P/E Ratio
$12.48
$11.39
Revenue Growth
N/A
N/A
52 Week Low
$43.90
$25.37
52 Week High
$75.43
$46.48

Technical Indicators

Market Signals
Indicator
HWC
TGTX
Relative Strength Index (RSI) 47.07 66.49
Support Level $63.03 $33.58
Resistance Level $64.42 $37.11
Average True Range (ATR) 1.32 1.50
MACD 0.33 0.37
Stochastic Oscillator 81.51 95.92

Price Performance

Historical Comparison
HWC
TGTX

About HWC Hancock Whitney Corporation

Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: